Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHA:600671)
China · Delayed Price · Currency is CNY 21.32
-0.21 (-0.98%)
Feb 27, 2026, 3:00 PM CST
SHA:600671 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 251.17 | 216.91 | 121.52 | 107.97 | 146.55 | 202.14 |
Other Revenue | 0.39 | 0.39 | 0.26 | 0.94 | 0.52 | 4.49 |
| 251.56 | 217.3 | 121.78 | 108.91 | 147.07 | 206.63 | |
Revenue Growth (YoY) | 56.88% | 78.44% | 11.82% | -25.95% | -28.82% | -30.45% |
Cost of Revenue | 130.48 | 116.62 | 98.37 | 93.74 | 106.45 | 130.29 |
Gross Profit | 121.07 | 100.68 | 23.41 | 15.16 | 40.62 | 76.34 |
Selling, General & Admin | 70.97 | 65.84 | 47.37 | 51.52 | 63.18 | 85.09 |
Research & Development | 1.1 | 1.21 | 0.48 | 1.58 | 1.33 | 0.64 |
Other Operating Expenses | 3.15 | 1.9 | 1.05 | 0.95 | 1.25 | 2 |
Operating Expenses | 77.6 | 71.24 | 45.91 | 59.05 | 69.81 | 91.46 |
Operating Income | 43.47 | 29.44 | -22.5 | -43.89 | -29.19 | -15.12 |
Interest Expense | -5.31 | -5.56 | -7.19 | -7.4 | -7.35 | -6.92 |
Interest & Investment Income | 0.19 | 0.48 | 0.11 | 1.02 | 0.1 | 0.1 |
Other Non Operating Income (Expenses) | -2.49 | 0.73 | -2.53 | -2.74 | -0.33 | -17.23 |
EBT Excluding Unusual Items | 35.86 | 25.09 | -32.1 | -53.01 | -36.78 | -39.17 |
Impairment of Goodwill | -0.58 | -0.58 | - | -0.53 | -2.92 | -15.38 |
Gain (Loss) on Sale of Investments | - | - | -0.53 | - | - | - |
Gain (Loss) on Sale of Assets | 0.1 | -0.21 | 0.15 | -0.09 | 0.04 | 1.72 |
Asset Writedown | -0.72 | - | -6.01 | -17.24 | - | -7.09 |
Other Unusual Items | 8.05 | 4.78 | 2.18 | -1.5 | 5.92 | 9.31 |
Pretax Income | 42.7 | 29.07 | -36.31 | -72.37 | -33.73 | -50.61 |
Income Tax Expense | 9.57 | 7.21 | 2.99 | 0.76 | -0.95 | 0.94 |
Earnings From Continuing Operations | 33.13 | 21.87 | -39.3 | -73.12 | -32.78 | -51.55 |
Minority Interest in Earnings | 0.02 | -6.62 | 1.02 | 5.61 | 2.98 | 11.03 |
Net Income | 33.15 | 15.25 | -38.28 | -67.52 | -29.8 | -40.52 |
Net Income to Common | 33.15 | 15.25 | -38.28 | -67.52 | -29.8 | -40.52 |
Shares Outstanding (Basic) | 122 | 122 | 122 | 122 | 124 | 123 |
Shares Outstanding (Diluted) | 122 | 122 | 122 | 122 | 124 | 123 |
Shares Change (YoY) | -0.26% | -0.01% | -0.00% | -1.92% | 1.13% | 0.83% |
EPS (Basic) | 0.27 | 0.13 | -0.31 | -0.55 | -0.24 | -0.33 |
EPS (Diluted) | 0.27 | 0.13 | -0.31 | -0.55 | -0.24 | -0.33 |
Free Cash Flow | -63.5 | -57.23 | -29.38 | -22.89 | -31.13 | -20.23 |
Free Cash Flow Per Share | -0.52 | -0.47 | -0.24 | -0.19 | -0.25 | -0.17 |
Gross Margin | 48.13% | 46.33% | 19.23% | 13.92% | 27.62% | 36.95% |
Operating Margin | 17.28% | 13.55% | -18.48% | -40.30% | -19.85% | -7.32% |
Profit Margin | 13.18% | 7.02% | -31.43% | -62.00% | -20.26% | -19.61% |
Free Cash Flow Margin | -25.24% | -26.34% | -24.13% | -21.02% | -21.17% | -9.79% |
EBITDA | 55.84 | 41.29 | -11.34 | -29.02 | -19.56 | -6.45 |
EBITDA Margin | 22.20% | 19.00% | -9.31% | -26.65% | -13.30% | -3.12% |
D&A For EBITDA | 12.36 | 11.85 | 11.16 | 14.86 | 9.64 | 8.66 |
EBIT | 43.47 | 29.44 | -22.5 | -43.89 | -29.19 | -15.12 |
EBIT Margin | 17.28% | 13.55% | -18.48% | -40.30% | -19.85% | -7.32% |
Effective Tax Rate | 22.40% | 24.79% | - | - | - | - |
Revenue as Reported | 251.56 | 217.3 | 121.78 | 108.91 | 147.07 | 206.63 |
Advertising Expenses | - | 1.19 | 0.9 | 0.77 | 0.46 | 1.53 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.